Section Arrow
AVTX.NASDAQ
- Avalo Therapeutics
Quotes are at least 15-min delayed:2024/05/13 07:55 EDT
Last
 10.85
-0.64 (-5.57%)
Day High 
11.59 
Prev. Close
11.49 
1-M High
18.79 
Volume 
57.55K 
Bid
10.4
Ask
11.6
Day Low
10.35 
Open
11.49 
1-M Low
11.25 
Market Cap 
11.88M 
Currency USD 
P/E -- 
%Yield
10-SMA 14.57 
20-SMA 14.17 
50-SMA 10.88 
52-W High 1,130.4 
52-W Low 3.9501 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-114.00/-0.97
Enterprise Value
25.37M
Balance Sheet
Book Value Per Share
7.06
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.92M
Operating Revenue Per Share
16.40
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NVAXNovavax8.88+4.41+98.66%-- 
DNAGinkgo Bioworks Holdings0.7609-0.1591-17.29%-- 
MGNXMacroGenics3.31-11.36-77.44%-- 
JAGXJaguar Health0.2921-0.0174-5.62%-- 
IOVAIovance Biotherapeutics10.965-2.485-18.48%-- 
Quotes are at least 15-min delayed:2024/05/13 07:55 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.